News releases
Date
Language

Type of release


Download

Full announcement
Dec 25, 2012

Ryzodeg® (insulin degludec/insulin aspart) approved in Japan

Bagsværd, Denmark, 25 December 2012 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ryzodeg® (insulin degludec/insulin aspart) for the treatment of diabetes.

Further information

Media:
Mike Rulis +45 4442 3573 mike@novonordisk.com
Ambre Morley (US) +1 609 216 5240 abmo@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 4442 4303 krop@novonordisk.com
Frank Daniel Mersebach +45 4442 0604 fdni@novonordisk.com
Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com
Jannick Lindegaard (US) +1 609 786 4575 jlis@novonordisk.com

Company announcement No 84 /2012